Osel and Partners Launch Phase IIb FLIP-2 Trial of Lactin-V

Why It Matters

Preterm birth remains a leading cause of neonatal mortality; an effective microbiome‑based prophylaxis could dramatically reduce health costs and improve outcomes worldwide. Successful trial data would position Lactin‑V as a first‑in‑class therapy, opening a sizable market for preventive obstetric care.

Key Takeaways

• FLIP‑2 will enroll 360 high‑risk pregnant women across four UK sites
• Lactin‑V contains live Lactobacillus crispatus to restore vaginal microbiome balance
• Phase I FLIP‑1 showed safety and lower preterm birth versus historical controls
• Osel holds exclusive global rights to Lactin‑V IP for preterm birth prevention
• Trial funded by NIHR Imperial Biomedical Research Centre and March of Dimes

Pulse Analysis

Preterm birth (PTB) accounts for roughly 10 percent of global deliveries and drives significant neonatal morbidity and health‑care expenses. Recent research highlights the vaginal microbiome’s role in triggering inflammatory pathways that can precipitate early labor. Lactin‑V, a live biotherapeutic product delivering Lactobacillus crispatus directly to the vagina, aims to re‑establish a protective microbial environment, potentially curbing inflammation and reducing PTB risk. By targeting the root cause rather than symptoms, this approach represents a paradigm shift from reactive to preventive obstetric care.

The FLIP‑2 Phase IIb trial, spearheaded by Imperial College London’s clinical trials unit and the March of Dimes, will assess both efficacy and safety in 360 high‑risk pregnant participants across four UK maternity units. Leveraging the promising safety profile and lower preterm‑birth rates observed in the earlier FLIP‑1 study, FLIP‑2 incorporates a randomized, double‑blind design to generate robust comparative data. Funding from the NIHR Imperial Biomedical Research Centre and the March of Dimes underscores public‑sector confidence in the therapy’s potential, while Osel’s exclusive global rights position it to commercialize successful outcomes.

If FLIP‑2 confirms Lactin‑V’s clinical benefit, the market implications are substantial. The global PTB prevention market is projected to exceed $2 billion within the next decade, driven by rising awareness and demand for non‑invasive interventions. A validated microbiome‑based product could attract partnerships with pharmaceutical giants, stimulate further research into live biotherapeutics for maternal health, and ultimately lower the economic burden of premature births on health systems. Osel’s strategic collaboration with leading academic and nonprofit partners places it at the forefront of this emerging therapeutic frontier.